Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

被引:9
作者
Cheng, Bai-Ru [1 ]
Wu, Rou-Yan [1 ]
Gao, Qin-Yang [1 ]
Jiang, Kai-Xin [2 ]
Li, Shuang-Sang [2 ]
Qi, Shi-Hao [2 ]
Yuan, Ming-Yi [2 ]
Liu, Jian-Ping [3 ]
机构
[1] Beijing Univ Chinese Med, Dongzhimen Hosp, Sch Clin Med 1, Beijing, Peoples R China
[2] Beijing Univ Chinese Med, Dongfang Hosp, Sch Clin Med 2, Beijing, Peoples R China
[3] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China
关键词
Xianling Gubao capsule; Chinese proprietary medicine; osteoporosis; quality of life; bone mineral density; systematic review; meta-analysis; DIFFERENTIATION; FRACTURES; COLLEGE;
D O I
10.3389/fendo.2022.870277
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the benefit and harm of Chinese medicine Xianling Gubao (XLGB) capsule compared to conventional medication or placebo to inform clinical practice. Methods: We included randomized controlled trials (RCTs) with Jadad score >= 3 of XLGB capsule compared to pharmaceutical medication, placebo, or no treatment for primary osteoporosis. We conducted searches in EMBASE, Cochrane CENTRAL, MEDLINE, China National Knowledge Infrastructure, VIP, Wanfang, and Chinese Biomedical Literature Database (Sino-Med) from their inception till November 13th, 2021. Study selection and data extraction were done by two authors independently. The methodological quality of the RCTs was assessed using Cochrane's risk of bias tool. The effect size was presented as risk ratio (RR) or mean difference (MD) with their 95% confidence interval (CI). Results: Our searches identified 2292 records and after exclusions, eight trials involving 846 participants were included. There was no statistically significant difference between conventional medications with or without XLGB on new fracture (RR: 0.50, 95% CI: [0.13, 1.87]). Quality of life by SF-36 questionnaire of XLGB plus calcium carbonate, vitamin D-3, and calcitriol was improved than that of without XLGB (MD: 6.72 scores, 95% CI: [2.82, 10.62]). XLGB increased bone mineral density similarly as calcium carbonate plus vitamin D-3 (MD: 0.21, 95% CI: [-0.16, 0.58]) or as alendronate sodium, calcium carbonate plus vitamin D-3 (MD: 0.00, 95% CI: [-0.10, 0.10]), but it had no additional effect as an add-on treatment to conventional medications (MD: 0.13, 95% CI: [-0.12, 0.37]). XLGB relieved pain via visual analog scale more effectively when combined with medications (MD: -1.55 score, 95% CI: [-2.47, -0.63]). XLGB as monotherapy did not increase adverse events (RR: 0.63, 95% CI: [0.28, 1.41]), or as an add-on treatment (RR: 0.25, 95% CI: [0.03, 2.16]). Conclusion: This systematic review shows that XLGB capsule appears to be safe and has a beneficial effect on the quality of life and pain relief when used alone or in combination with conventional medications in osteoporosis patients. Further large, rigorous trials are warranted to test its long-term benefit.
引用
收藏
页数:11
相关论文
共 43 条
[1]   Trends in Fracture Incidence: A Population-Based Study Over 20 Years [J].
Amin, Shreyasee ;
Achenbach, Sara J. ;
Atkinson, Elizabeth J. ;
Khosla, Sundeep ;
Melton, L. Joseph, III .
JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (03) :581-589
[2]  
Bauer DC, 2014, NEW ENGL J MED, V370, P387, DOI [10.1056/NEJMc1314100, 10.1056/NEJMcp1210380]
[3]   Postmenopausal Osteoporosis [J].
Black, Dennis M. ;
Rosen, Clifford J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03) :254-262
[4]   Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis [J].
Bolland, Mark J. ;
Grey, Andrew ;
Avenell, Alison ;
Gamble, Greg D. ;
Reid, Ian R. .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 342
[5]  
Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL-2020-0524SUPPL
[6]   Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways [J].
Chen, Huiwen ;
Fang, Chao ;
Zhi, Xin ;
Song, Shaojun ;
Gu, Yanqiu ;
Chen, Xiaofei ;
Cui, Jin ;
Hu, Yan ;
Weng, Weizong ;
Zhou, Qirong ;
Wang, Yajun ;
Wang, Yao ;
Jiang, Hao ;
Li, Xiaoqun ;
Cao, Liehu ;
Chen, Xiao ;
Su, Jiacan .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (16) :9067-9084
[7]   The mechanism of Epimedin B in treating osteoporosis as revealed by RNA sequencing-based analysis [J].
Diao, Xinyue ;
Wang, Liwen ;
Zhou, Yating ;
Bi, Yanan ;
Zhou, Kun ;
Song, Lei .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 129 (06) :450-461
[8]  
Feng MM., 2014, TIANJIN PHARM, V26, P44
[9]  
Fu Y., 2021, Chin. J. Gerontol., V41, P5015, DOI [10.3969/j.issn.1005-9202.2021.22.043, DOI 10.3969/J.ISSN.1005-9202.2021.22.043]
[10]   Isopsoralen Enhanced Osteogenesis by Targeting AhR/ERα [J].
Ge, Luna ;
Cui, Yazhou ;
Cheng, Kai ;
Han, Jinxiang .
MOLECULES, 2018, 23 (10)